Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

伊库利珠单抗 阵发性夜间血红蛋白尿 医学 临床终点 不利影响 内科学 随机对照试验 胃肠病学 免疫学 补体系统 抗体
作者
Phillip Scheinberg,Diego V. Clé,Jin Seok Kim,Erfan Nur,Mustafa Nuri Yenerel,Wilma Barcellini,Debora Bonito,Valentina Giai,Marek Hus,Yoojin Lee,Cristina Barrenetxea Lekue,Jens Panse,Yasutaka Ueda,Simon Buatois,Brittany Gentile,Anna Kiialainen,Himika Patel,Sasha Sreckovic,Marianne Uguen,John Edwards
出处
期刊:American Journal of Hematology [Wiley]
卷期号:99 (9): 1757-1767 被引量:41
标识
DOI:10.1002/ajh.27413
摘要

Crovalimab, a novel C5 inhibitor, allows for low-volume, every-4- week, subcutaneous self-administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH). Adults with lactate dehydrogenase ≤1.5 × upper limit of normal and receiving approved eculizumab doses for ≥24 weeks were randomized 1:1 to receive crovalimab (weight-based tiered dosing) or continue eculizumab. The original primary study objective was efficacy; however, given the evolving treatment landscape, target recruitment was not met, and all efficacy endpoints became exploratory, with safety as the new primary objective. Exploratory efficacy endpoints included transfusion avoidance, hemolysis control, breakthrough hemolysis, hemoglobin stabilization, FACIT-Fatigue score, and patient preference (crovalimab vs. eculizumab). Eighty-nine patients were randomized (45 to crovalimab; 44 to eculizumab). During the 24-week primary treatment period, adverse events (AEs) occurred in 77% of patients receiving crovalimab and 67% receiving eculizumab. No AEs led to treatment withdrawal or death, and no meningococcal infections occurred. 16% of crovalimab-treated patients had transient immune complex reactions (also known as Type III hypersensitivity events), an expected risk when switching between C5 inhibitors that bind to different C5 epitopes; most were mild/moderate and all resolved without treatment modification. Crovalimab-treated patients had sustained terminal complement activity inhibition, maintained disease control, and 85% preferred crovalimab over eculizumab. Together with phase 3 COMMODORE 2 results in complement inhibitor-naive patients, these data support crovalimab's favorable benefit-risk profile. Crovalimab is a new C5 inhibitor for PNH that is potentially less burdensome than existing therapies for this lifelong disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
幽默的盼山完成签到,获得积分10
1秒前
传奇3的应助被徐枘采纳,获得10
1秒前
牛黄完成签到 ,获得积分10
1秒前
2秒前
2秒前
2秒前
3秒前
栗子完成签到,获得积分10
3秒前
3秒前
drizzle发布了新的文献求助10
3秒前
哈哈完成签到,获得积分20
3秒前
叮叮当当发布了新的文献求助10
4秒前
4秒前
JamesPei的应助被学习采纳,获得10
4秒前
4秒前
zhaoben发布了新的文献求助10
4秒前
阿皮的应助被dxxxxx采纳,获得30
4秒前
5秒前
hc发布了新的文献求助10
6秒前
yjt发布了新的文献求助10
7秒前
WZJ完成签到,获得积分20
7秒前
7秒前
8秒前
8秒前
8秒前
8秒前
热情曲奇发布了新的文献求助30
9秒前
liu完成签到,获得积分10
9秒前
fan的应助被科研通管家采纳,获得10
10秒前
SciGPT的应助被科研通管家采纳,获得20
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
10秒前
汉堡包的应助被科研通管家采纳,获得10
10秒前
sun发布了新的文献求助10
10秒前
科研通AI65的应助被科研通管家采纳,获得10
10秒前
速写发布了新的文献求助10
10秒前
曾经凌萱发布了新的文献求助30
10秒前
无情愫的应助被科研通管家采纳,获得20
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817